Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1271-1280 of 1,779) with videos related to

Pageof 178
Sort By:
Mabs|March 21, 2024
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeuticsRuoxuan Sun, Mark G Qian, Xiaobin Zhang
Mabs|March 28, 2024
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based <i>in silico</i> approachesDavid Hoffmann, Joschka Bauer, Markus Kossner, et al.
Mabs|February 19, 2024
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagersAmmelie Svea Boje, Lukas Pekar, Katharina Koep, et al.
Mabs|March 5, 2024
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsSophie Tourdot, Daniel Baltrunkonis, Sofie Denies, et al.
Mabs|February 1, 2024
<i>In-situ</i> biophysical characterization of high-concentration protein formulations using <i>w</i>NMRJing Song, Marc Taraban, Y Bruce Yu, et al.
Mabs|August 2, 2023
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1Mengzhen Jiang, Man Liu, Guodi Liu, et al.
Mabs|March 21, 2026
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutionsJohn C Shelley, Qing Chai, Lina Wu, et al.
Mabs|April 7, 2026
Deep learning assessment of nativeness and pairing likelihood for antibody and nanobody design with AbNatiV2Aubin Ramon, Niccolò Frassetto, Haowen Zhao, et al.
Mabs|April 23, 2024
Alternative splicing for tuneable expression of protein subunits at desired ratiosChristel Aebischer-Gumy, Pierre Moretti, Timothee Brunstein Laplace, et al.
Mabs|April 13, 2026
Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab betaQing Shuang, Mingze Sun, Guangzhong Lin, et al.
Pageof 178

Showing results (1271-1280 of 1,779) with videos related to

Sort By:
Pageof 178
Mabs|March 21, 2024
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeuticsRuoxuan Sun, Mark G Qian, Xiaobin Zhang
Mabs|March 28, 2024
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based <i>in silico</i> approachesDavid Hoffmann, Joschka Bauer, Markus Kossner, et al.
Mabs|February 19, 2024
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagersAmmelie Svea Boje, Lukas Pekar, Katharina Koep, et al.
Mabs|March 5, 2024
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsSophie Tourdot, Daniel Baltrunkonis, Sofie Denies, et al.
Mabs|February 1, 2024
<i>In-situ</i> biophysical characterization of high-concentration protein formulations using <i>w</i>NMRJing Song, Marc Taraban, Y Bruce Yu, et al.
Mabs|August 2, 2023
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1Mengzhen Jiang, Man Liu, Guodi Liu, et al.
Mabs|March 21, 2026
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutionsJohn C Shelley, Qing Chai, Lina Wu, et al.
Mabs|April 7, 2026
Deep learning assessment of nativeness and pairing likelihood for antibody and nanobody design with AbNatiV2Aubin Ramon, Niccolò Frassetto, Haowen Zhao, et al.
Mabs|April 23, 2024
Alternative splicing for tuneable expression of protein subunits at desired ratiosChristel Aebischer-Gumy, Pierre Moretti, Timothee Brunstein Laplace, et al.
Mabs|April 13, 2026
Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab betaQing Shuang, Mingze Sun, Guangzhong Lin, et al.
Pageof 178